Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 91 to 105 of 157 results for thrombosis

  1. Total hip replacement and resurfacing arthroplasty for end-stage arthritis of the hip (TA304)

    Evidence-based recommendations on artificial hips and hip resurfacing for treating end-stage arthritis of the hip in adults.

    Technology appraisal guidance
    Published
    26 February 2014
    View recommendations

    Sections for TA304

  2. Living-donor liver transplantation (IPG535)

    Evidence-based recommendations on living-donor liver transplantation. This involves replacing a diseased or damaged liver with a healthy one from a living human donor.

    Interventional procedures guidance
    Published
    25 November 2015
    View recommendations

    Sections for IPG535

  3. Ravulizumab for treating atypical haemolytic uraemic syndrome (TA710)

    Evidence-based recommendations on ravulizumab (Ultomiris) for treating atypical haemolytic uraemic syndrome in people weighing 10 kg or more.

    Technology appraisal guidance
    Published
    23 June 2021
    View recommendations

    Sections for TA710

  4. Selective internal radiation therapies for treating hepatocellular carcinoma (TA688)

    Evidence-based recommendations on selective internal radiation therapies SIR-Spheres (Sirtex), TheraSphere (BTG) and QuiremSphere (Quirem Medical) for treating hepatocellular carcinoma in adults.

    Technology appraisal guidance
    Last updated
    3 July 2024
    View recommendations

    Sections for TA688

  5. COVID-19 rapid guideline: vaccine-induced immune thrombocytopenia and thrombosis (VITT) (NG200)

    This guideline has been withdrawn. VITT is associated with the COVID-19 Vaccine AstraZeneca, which is no longer available from the NHS. For people with COVID-19, see our guideline on managing COVID-19.

    COVID-19 rapid guideline
    Last updated
    22 June 2022

  6. Early and locally advanced breast cancer: diagnosis and management (NG101)

    This guideline covers diagnosing and managing early and locally advanced breast cancer. It aims to help healthcare professionals offer the right treatments to people, taking into account the person's individual preferences.

    NICE guideline
    Last updated
    14 April 2025
    View recommendations

    Sections for NG101

  7. Iptacopan for treating paroxysmal nocturnal haemoglobinuria (TA1000)

    Evidence-based recommendations on iptacopan (Fabhalta) for treating paroxysmal nocturnal haemoglobinuria in adults.

    Technology appraisal guidance
    Published
    4 September 2024

    Sections for TA1000

  8. Ranibizumab for treating visual impairment caused by macular oedema secondary to retinal vein occlusion (TA283)

    Evidence-based recommendations on ranibizumab (Lucentis) for treating visual impairment caused by macular oedema secondary to retinal vein occlusion in adults.

    Technology appraisal guidance
    Last updated
    20 May 2024
    View recommendations

    Sections for TA283

  9. HemaClear for bloodless surgical field during limb surgery (MIB187)

    NICE has developed a medtech innovation briefing (MIB) on HemaClear for bloodless surgical field during limb surgery .

    Medtech innovation briefing
    Published
    15 July 2019

  10. Abortion care (NG140)

    This guideline covers care for women of any age (including girls and young women under 18) who request an abortion. It aims to improve the organisation of services and make them easier for women to access. Detailed recommendations on conducting abortions at different gestational stages are also included, to ensure that women get the safest and most effective care possible.

    NICE guideline
    Last updated
    27 May 2025
    View recommendations

    Sections for NG140

  11. Current evidence on the safety of percutaneous mechanical thrombectomy for acute deep vein thrombosis (DVT) of the leg shows there are well-recognised but infrequent complications. For distal DVT that does not extend into the common femoral vein the evidence on efficacy is inconclusive, therefore this procedure should only be used in the context of  research .

    the safety of percutaneous mechanical thrombectomy for acute deep vein thrombosis (DVT) of the leg shows there are well-recognised but...

    Research recommendation
    Published
    15 November 2019

  12. Current evidence on the safety of percutaneous mechanical thrombectomy for acute deep vein thrombosis (DVT) of the leg shows there are well-recognised but infrequent complications. For acute iliofemoral DVT the evidence on efficacy is limited in quality and quantity, therefore this procedure should only be used with  special arrangements   for clinical governance, consent, and audit or research.

    the safety of percutaneous mechanical thrombectomy for acute deep vein thrombosis (DVT) of the leg shows there are well-recognised but...

    Research recommendation
    Published
    27 May 2020

  13. WoundExpress to manage lower leg wounds (MIB261)

    NICE has developed a medtech innovation briefing (MIB) on WoundExpress to manage lower leg wounds .

    Medtech innovation briefing
    Published
    1 June 2021

  14. Familial breast cancer. Patient decision aid on taking tamoxifen to reduce the chance of developing breast cancer for premenopausal women at moderately increased risk

    difference will it make to my chance of getting a blood clot such as deep vein thrombosis (DVT) or a blood clot in the lungs (pulmonary...

  15. Familial breast cancer. Patient decision aid on taking tamoxifen to reduce the chance of developing breast cancer for premenopausal women at high risk

    difference will it make to my chance of getting a blood clot such as deep vein thrombosis (DVT) or a blood clot in the lungs (pulmonary...